Skip to main content
. 2022 Dec 9;22:467. doi: 10.1186/s12883-022-02998-3

Table 2.

Individual NPSLE manifestations in 72 SLE patients

NPSLE-manifestation SLICC A model SLICC B model ACR model
Any NPSLE-manifestation, n (%) 16 (22%) 23 (32%) 44 (61%)
Cognitive dysfunction, n (%) 0 (0%) 5 (7%) 26 (36%)
Headache, n (%) N/A N/A 22 (31%)
Depression, n (%) 0 (0%) 1 (1%) 13 (18%)
Anxiety disorder, n (%) N/A N/A 12 (17%)
Autonomic neuropathy, n (%) 7 (10%) 8 (11%) 10 (14%)
Cranial neuropathy, n (%) 7 (10%) 7 (10%) 7 (10%)
Cerebrovascular disease, n (%) 1 (1%) 5 (7%) 5 (7%)
Demyelinating disease, n (%) 3 (4%) 3 (4%) 3 (4%)
Myelopathy, n (%) 2 (3%) 3 (4%) 3 (4%)
Acute confusional state, n (%) 1 (1%) 2 (3%) 3 (4%)
Polyneuropathy, n (%) 1 (1%) 1 (1%) 3 (4%)
Seizures, n (%) 1 (1%) 2 (3%) 2 (3%)
Mononeuritis, n (%) 1 (1%) 2 (3%) 2 (3%)
Aseptic meningitis, n (%) 1 (1%) 1 (1%) 1 (1%)
Psychosis, n (%) 1 (1%) 1 (1%) 1 (1%)
Chorea, n (%) 0 (0%) 1 (1%) 1 (1%)
Guillain-Barré syndrome, n (%) 0 (0%) 0 (0%) 0 (0%)
Plexopathy, n (%) 0 (0%) 0 (0%) 0 (0%)
Myasthenia gravis, n (%) 0 (0%) 0 (0%) 0 (0%)

One patient may have more than one NPSLE-manifestation

NPSLE Neuropsychiatric Systemic Lupus Erythematosus, SLICC Systemic Lupus Erythematosus International Collaborating Clinics, ACR American College of Rheumatology, N/A Not applicable